The K2 Principal Fund L.P. Acquires Common Shares of Tribute Pharmaceuticals Canada Inc.

TORONTO, June 8, 2015 /CNW/ - The K2 Principal Fund L.P. ("K2") announced that it has acquired 8,024,025 common shares. Previously K2 owned 4,700,000 common share purchase warrants (the "Warrants") to purchase up to 4,700,000 common shares of Tribute Pharmaceuticals Canada Inc. (TRX) at an exercise price of $0.90 per share.  The warrants expire on July 15^th, 2016.  As a result of the acquisition of such shares and previously purchased warrants, and assuming the exercise of the Warrants in full, the Partnership would own 12,724,025 common shares, representing approximately 10.74% of the issued and outstanding common shares of TRX.

K2 acquired the securities for investment purposes only and may, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over, or exercise its current rights to acquire, common shares or other securities of TRX through market transactions, private agreements or otherwise. 

SOURCE K2 Principal Fund L.P.

Dan Gosselin, The K2 Principal Fund L.P., [phone]